Boothbay Fund Management LLC Raises Stake in Vaxcyte, Inc. $PCVX

Boothbay Fund Management LLC raised its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 286.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 497,740 shares of the company’s stock after purchasing an additional 369,009 shares during the period. Vaxcyte accounts for 0.3% of Boothbay Fund Management LLC’s investment portfolio, making the stock its 12th largest holding. Boothbay Fund Management LLC’s holdings in Vaxcyte were worth $22,966,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in PCVX. Royal Bank of Canada lifted its holdings in Vaxcyte by 115.2% during the first quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock valued at $1,113,000 after purchasing an additional 15,774 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Vaxcyte during the first quarter valued at approximately $219,000. Caxton Associates LLP purchased a new position in Vaxcyte during the first quarter valued at approximately $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Vaxcyte by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock valued at $19,409,000 after purchasing an additional 41,034 shares in the last quarter. Finally, Cetera Investment Advisers lifted its holdings in Vaxcyte by 13.8% during the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock valued at $250,000 after purchasing an additional 932 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on PCVX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Wall Street Zen downgraded shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a report on Tuesday, March 10th. Finally, BTIG Research boosted their target price on shares of Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vaxcyte presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

Vaxcyte Stock Performance

PCVX stock opened at $50.67 on Thursday. Vaxcyte, Inc. has a one year low of $29.08 and a one year high of $65.00. The company’s fifty day moving average price is $53.74 and its 200-day moving average price is $52.69. The company has a market capitalization of $7.32 billion, a PE ratio of -7.36 and a beta of 1.24.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the previous year, the firm earned ($1.04) EPS. On average, research analysts predict that Vaxcyte, Inc. will post -7.56 EPS for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In related news, COO Jim Wassil sold 2,250 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $49.52, for a total transaction of $111,420.00. Following the sale, the chief operating officer owned 158,494 shares of the company’s stock, valued at $7,848,622.88. This represents a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of the company’s stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total transaction of $180,000.00. Following the sale, the chief accounting officer directly owned 28,975 shares in the company, valued at approximately $1,738,500. The trade was a 9.38% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,500 shares of company stock worth $419,288 in the last three months. Insiders own 3.30% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.